Pesquisar
Unicycive Therapeutics Inc
UNCYAdicionar à lista de desejos
5.010USD
-0.290-5.47%
Fechamento 07-31 16:00（ET）Cotações atrasadas em 15 min
133.77MValor de mercado
PerdaP/L TTM
Mais detalhes de Unicycive Therapeutics Inc Empresa
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Informações de Unicycive Therapeutics Inc
Código da empresaUNCY
Nome da EmpresaUnicycive Therapeutics Inc
Data de listagemJun 17, 2021
CEOGupta (Shalabh)
Número de funcionários22
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 17
Endereço4300 El Camino Real, Suite 210
CidadeLOS ALTOS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94022
Telefone16503840642
Sitehttps://unicycive.com/
Código da empresaUNCY
Data de listagemJun 17, 2021
CEOGupta (Shalabh)
Executivos da empresa Unicycive Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
+0.01%
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
+0.01%
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Unicycive Therapeutics Inc?
Os cinco principais acionistas de Unicycive Therapeutics Inc são: Dr. Sandeep (Steve) Laumas, M.D.
Quantas instituições possuem ações da Unicycive Therapeutics Inc (UNCY)?
Em 2026Q1, 75 instituições possuíam ações da Unicycive Therapeutics Inc, com valor de mercado aproximado de 9.56M, representando 35.81% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 450872.00.